View Article Online View Journal

MedChemComm

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: H. Singh, J. V. Singh, A. Kaur, K. Bhagat, M. K. Gupta, M. Singh and P. M. Singh Bedi, *Med. Chem. Commun.*, 2018, DOI: 10.1039/C7MD00565B.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the **author guidelines**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the ethical guidelines, outlined in our <u>author and reviewer resource centre</u>, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



rsc.li/medchemcomm

5,6-Benzoflavones as cholesterol esterase inhibitors: Synthesis, biological evaluation and docking studies

Jatinder V. Singh^I,^a, Anumeet Kaur^I,^a, Kavita Bhagat^a, Manish K. Gupta^b, Manwinder Singh^c, Harbinder Singh^{*},^a, Preet Mohinder S. Bedi^{*},^a

^aDepartment of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India

^bTERI-Deakin Nanobiotechnology Centre, The Energy and Resources Institute, TERI Gram, Gual Pahari, Gurugram, Haryana 122001, India

^cDepartment of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India

Corresponding author: 1) Harbinder Singh

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India Mob no. +919463148367

2) Dr. P.M.S. Bedi

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India Mob no. +919815698249

¹These authors contributed equally to this work.

MedChemComm

Abstract: In continuous efforts to develop potent cholesterol esterase (CEase) inhibitors, a series of 5,6-benzoflavone derivatives was rationally designed and synthesized by changing the position of benzene ring attached to flavone skeleton in previously reported (7,8-benzoflavones). All the synthesized compounds were checked for their inhibitory potential against cholesterol esterase (CEase) by using spectrophotometric assay. Among the series of forty compounds, seven derivatives (**B-10** to **B-16**) exhibited above 90 percent inhibition against CEase in *in-vitro* enzymatic assay. Compound **B-16** showed the most promising activity with IC₅₀ value of 0.73 nM against cholesterol esterase. To determine the type of inhibition, enzyme kinetic studies were carried out for **B-16**, which revealed its mixed-type inhibition approach. Moreover, to figure out the key binding interactions of **B-16** with the amino acid residues of the enzyme's active site, molecular protein–ligand docking studies were also performed. The **B-16** completely blocks the catalytic assembly of CEase and prevents it to participate in ester hydrolysis mechanism. The favorable binding conformation of **B-16** suggests its prevailing role as CEase inhibitor. The overall study stated that the *cis*-orientation of Ring A with respect to carbonyl group of Ring C is responsible for potent CEase inhibitory activity of newly synthesized compounds.

Keywords: 5,6-benzoflavones, Baker Venkataraman rearrangement, cholesterol esterase inhibition, enzyme kinetics, docking studies.

Introduction:

Cholesterol is a vital component of cell membrane which possesses many physiological functions. Plasma cholesterol level is linked to many diseases such as coronary artery disease, cancer, obesity, and diabetes, which is a major health aim worldwide.¹ In this respect, control of the cholesterol level has gained much attention.

Pancreatic cholesterol esterase (CEase) is an important serine hydrolase that plays imperative role in the absorption of dietary cholesterol. The transport of cholesterol micelles to enterocytes is also performed by this enzyme.² As its dual role in absorption and transportation, the inhibition of CEase is very important and thus a potential approach to treat hypercholesterolemia and atherosclerosis.³ In the recent past, several classes of potent CEase inhibitors have been developed including aryl phosphates and phosphonates,⁴ carbamates,⁵ chloroisocoumarins,⁶ 6-chloro-2-pyrones,⁷ 2-(1H-Indol-3-yl)-4-phenylquinolines,⁸ 3-phenyl substituted 1,3,4-oxadiazol-2(3H)-ones,⁹ phosphaisocoumarins,¹⁰ phosphorylated flavonoids,¹¹ thiazolidinediones,² and thieno[1,3]-oxazin-4-ones¹² (**Figure 1**). However, most of the reported inhibitors are not highly selective for CEase and could also inhibit other serine hydrolases, such as acetylcholinesterase (AChE), butylcholinesterase (BuChE), Pseudomonas species lipase, chymotrypsin and trypsin.^{3,13-16} One of the major reasons behind their in-selectivity is that all serine enzymes share the similar catalytic triad of Ser-His-Asp (Glu) and mechanism of acylatione-deacylation.¹⁷

Inspired from various biological attributes of flavones, we have recently reported a series of 7,8benzoflavone derivatives as potential CEase inhibitors.¹⁸ Among this whole series of compounds, twenty seven molecules were found to exhibit above 60% inhibition against CEase enzyme with the IC₅₀ values ranging from 0.78 to 47.80 nM. Compound **A** was the most promising molecule among the series of reported molecules (**Figure 2**). Prompted from these significant *in-vitro* results, a new series of the compounds have been designed by simply changing the orientation of Ring A, from *trans-* to *cis*-configuration with respect to carbonyl group of Ring C (**Figure 2**). Docking study demonstrated that, Ring A gets positioned in a welldefined cavity formed by Gly106, Gly107, GLu193, Ser194 and Ala19 within the active site of CEase. While, Ring A of 7,8-benzoflavone derivatives only surrounded by Ile323 and His435 amino acid residues. We concluded from these particular findings that the *cis*-orientation of Ring A with respect to carbonyl group of Ring C might be responsible for good CEase inhibitory activity of newly designed compounds. In present study, the designed compounds were synthesized in order to evaluate the inhibitory potential against CEase enzyme by using *in-vitro* spectrophotometric assay. The type of inhibition and the various types of interactions of the most potent inhibitor with CEase had also been figured out.

Results and Discussion:

5,6-benzoflavone derivatives were synthesized *via* Scheme 1. β-naphthol was subjected to fries rearrangement and the product (1) was benzoylated using benzoylchloride to obtain 2. Product 2 was then subjected to Baker Venkataraman rearrangement. The Baker Venkataraman rearranged product (3) existed in enol form (confirmed by the appearance of singlet for two D₂O exchangeable protons at 11.35 ppm along with the vinylic proton to carbonyl which appeared as a merged signal in a multiplet at 7.26-7.36 ppm). Compound 3 was then cyclized by treatment with sulphuric acid to yield the desired 5,6-benzoflavone (B-1). Some of the synthesized molecules are previously reported by various research groups (mentioned below) but most of the molecules reported herein are novel to the best of our knowledge. All the reactions proceeded smoothly with diverse benzoylchlorides (Table 1) and products were obtained in good yields. No Retro-Diels fragmentation was observed for derivatives in the mass spectrum. The structures of the synthesized compounds were elucidated by ¹H NMR, ¹³C NMR and MASS spectrum. All spectral data were in accordance with assumed structures.

In vitro screening:

Published on 19 January 2018. Downloaded by Nagoya Daigaku on 19/01/2018 16:42:03.

CEase inhibition assay of all the synthetics was performed by using spectrophotometric assay as described in the literature⁸ and the results were compared with potent cholesterol esterase inhibitor (**PF**) reported by Wei Y *et al.*¹¹

In-vitro results showed that among series of forty compounds, nine compounds exhibited significant percentage inhibition against CEase enzyme (above 90 % inhibition). Compound **B-16** was found to be endowed with most potent percentage inhibition against CEase with 100% inhibition. Careful examination of **Table 1** revealed an interesting structure activity relationship similar to the reported benzoflavone derivatives (7,8-benzoflavones) as CEase inhibitors. Any substitution on Ring D [phenyl (at 2nd position of 5,6-benzoflavone)] significantly influences the cholesterol esterase inhibitory activity. Placement of halogen atoms on this phenyl ring

considerably increases the potency against cholesterol esterase enzyme. It has also been cleared that as the size of halogen atom increases, inhibitory potency significantly decreases. Ring D (phenyl) with deactivating groups (nitro, cholomethyl, trifloromethyl and acetoxy) favors the inhibitory activity whereas, Ring D with activating groups (dimethylamino, methoxy, methyl and trifloromethoxy), disfavors the activity against CEase inhibition. Thus, the overall preference order of the substituent on phenyl ring at 2nd position of 5,6-benzoflavone nucleus for the inhibition of cholesterol esterase enzyme is as follows: $-Cl > -F > -Br > -I > -NO_2 > -CH_2Cl > CF_3 > -OCOCH_3 > -H > -OCF_3 > -CH_3 > -OCH_3 > -N(CH_3)_2$ (Figure 3). Compounds with CEase enzyme inhibition of more than 60% at 50 nM were further evaluated at four different concentrations (1, 5, 10 and 25 nM) in order to calculate their IC₅₀ values. Exceptionally, the IC₅₀ value of unsubstituted compound B-1 was also calculated to better describe the structure activity relationship. The IC₅₀ value of most potent compound B-16 (0.73 nM) was found comparable to that of literature value of phosphorylated flavonoid (PF, $IC_{50} = 0.72 \text{ nM}$)¹¹ (Table 1). Most excitingly, the whole series was found to be more active as compare to the previous series of compounds (7,8-benzoflavones) with the IC₅₀ values ranging from 0.72-31.35. Moreover, the experimentation for the evaluation to check the specificity of most potent compound towards the cholesterol esterase enzyme is also under progress.

Enzyme kinetics study:

The most potent compound among the series (**B-16**) was further investigated for the type of inhibition by performing enzyme kinetic studies.¹⁹ The Lineweaver-Burk plot (**Figure 4**) revealed that the compound **B-16** was a mixed-type CEase inhibitor. The pattern of graph shows that it is a form of mixed inhibition scenario. The K_m, V_{max} and slope are all affected by the inhibitor. The inhibitor has increased the K_m and slope (K_m/V_{max}) while decreasing the V_{max}. Moreover carefully observing the **Figure 4** it was found that intersecting lines on the graph converge to the left of the *y*-axis and above the *x*-axis which indicates that the value of α (a constant that defines the degree to which inhibitor binding affects the affinity of the enzyme for substrate) is greater than 1. This confirms that the inhibitor preferentially binds to the free enzyme and not to the enzyme substrate complex.

Docking studies:

Various types of the binding interactions of most potent compound **B-16** within the active site of *human* cholesterolesterase enzyme (*h*CEase), were also streamlined by using molecular modeling studies. The active site apparatus of *h*CEase consist of a catalytic triad and an oxyanion hole.²⁰ The catalytic triad is made of Ser194, Asp320, and His435 residues and serves as general acid-base and nucleophilic catalytic entity along with an oxyanion hole consisting of Gly107, Ala108, and Ala195 residues.^{20,21} The hydroxyl group of Ser194 acts as nucleophile and is necessary for the hydrolytic reaction. The serine lipases and serine proteases also possess the Ser-Asp-His catalytic triad and share the catalytic mechanism with *h*CEase. In the present docking study, the *h*CEase residues within the radius of 10 Å around the hydroxyl function of Ser194 were defined to form the active site of the enzyme.²¹

The **B-16** fits well at the catalytic site and stabilized by H-bonds, polar and van der Walls interactions (**Figure 5** and **6**). Interestingly, the Gly107, Ala108, and Ala195 residues of oxyanion hole were involved in H-bond interactions with the carbonyl oxygen of Ring C (H-bond acceptor; d = 2.01 to 2.19 Å). The three H-bonds showed their significance in the tight binding of **B-16** with *h*CEase. Rings A, B and C were stabilized by van der Waals interaction with Ser194, His435 and Ala436. In addition to this, the Ring C of **B-16** is placed in a well-defined cavity formed by Gly106, Gly107, Glu193, Ser194 and Ala195 and suggested to be stabilized by dispersion interactions. Ring D (dichlorophenyl) gets positioned in a hydrophobic cavity created by Trp227, Phe324, Leu392 and Phe393 residues and involved in face-to-face paipai stacking interaction with Trp227 and Phe324. The study showed that the **B-16** completely blocks the catalytic assembly of *h*CEase. Its binding with the oxyanion hole prevents it to participate in ester hydrolysis mechanism. The favorable binding conformation of **B-16** suggests its prevailing role as *h*CEase inhibitor.

While comparing the docking conformation of **B-16** and **A** (lead compound), the **B-16** showed more strong binding with *h*CEase as shown by higher Gold score than **A** (Gold score = 54.35 and 46.06 for **B-16** and **A**, respectively). Both compounds shared common pharmacophoric features except the position of Ring A (**Figure 2**). In contrary to **B-16**, the Ring A of "compound **A**" is in *trans* conformation to the carbonyl function at Ring C and surrounded by Ile323 and His435 only. Therefore, this can be suggested that *cis*-conformation of Ring A and carbonyl function at

Ring C is more favorable for activity than *trans*-conformation. This pattern of docking is in full agreement with the *in-vitro* results. (Figure 7).

In silico studies:

Furthermore, physico-chemical properties like Absorption, Distribution, Metabolism and Excretion (ADME) of the synthesized compounds were determined in silico by using the webbased applications MarvinSketch (http://www.chemaxon.com/) and PreADMET (http://preadmet.bmdrc.org/). The Caco-2 cell, MDCK cell, Blood Brain Barrier (BBB) & Skin permeabilities, human intestinal absorption and plasma protein binding affinities were predicted and summarized in Table 2. Results indicated that the compounds are predicted to have lower blood brain barrier permeation which are less likely to cause neurotoxicity. In other words we can say that the synthesized compounds cannot alter the normal activity of the neuronal cells. Basicity and lipophilicity of the synthesized compounds were determined with ChemAxon software MarvinSketch and the results are shown in Table 3 which describes the compliance of all the synthesized compounds with the Lipinski rule of five. Tabular values indicated that a) all the molecules have molecular weight in the range of 286-408 which lies in the limit of 180-500 b) compounds have no H-bond donating property c) compounds followed the H-bond acceptor criteria (< 10) d) molar refractivity found very consistence in the range of 83.64-98.07 which lies well in the accepted value range 40-130 and e) a log P of all the compounds found lower than 5.6 indicating that the compounds are not very lipophilic. These results suggest that all the compounds follow the Lipinski rule of five and ADME properties which makes them pharmacologically efficient for clinical use in future.

Conclusion:

A series of 5,6-benzoflavone derivatives rationally designed, synthesized and characterized by using ¹H NMR, ¹³C NMR, MASS and Elemental Analysis. All the synthetics were evaluated for *in-vitro* cholesterol esterase inhibitory activity. Among all the derivatives, **B-16** was found to be endowed with most potent enzyme inhibition with IC_{50} value of 0.73 nM. Enzyme kinetic study confirmed that the inhibitor **B-16** preferentially binds to the free enzyme and not to the enzyme substrate complex (mixed type inhibition). Docking study suggested that the compound **B-16** fits well in the active site of cholesterol esterase enzyme and completely blocks its catalytic

assembly. The study also concluded that *cis*-conformation of Ring A and carbonyl function at Ring C is well tolerable for CEase inhibition. In silico parameters revealed that the compounds with improved CEase inhibitory potential could be act as a hit lead molecules for further development of pharmacologically active CEase inhibitory framework.

Experimental:

Published on 19 January 2018. Downloaded by Nagoya Daigaku on 19/01/2018 16:42:03.

Materials and measurements

The reagents were purchased from Sigma Aldrich, Loba and CDH, India and used without further purification. The porcine cholesterol esterase enzyme was also procured from Sigma Aldrich. All yields refer to isolated products after purification. Products were characterized by comparison with authentic samples and by spectroscopic data (¹H, ¹³C NMR and MASS). ¹H NMR and ¹³C NMR Spectra were recorded on JEOL AL 300 NMR Spectrometer. The spectra were measured in CDCl₃ relative to TMS (0.00 ppm). In ¹H NMR chemical shifts were reported in δ values using tetramethylsilane as internal standard with number of protons, multiplicities (s-singlet, d-doublet, t-triplet, q-quartet, m-multiplet, dd-double doublet) and coupling constants (*J*) in Hz (Hertz) in the solvent indicated. HRMS was recorded on micrOTOF-QII Bruker Daltonik LC–MS/MS High Resolution Mass Spectrometer. Melting points were determined in open capillaries and were uncorrected.

Procedure for Synthesis of 1-(2-hydroxynaphthalen-1-yl)ethanone (1)

 β -naphthol (1mmol) was treated with glacial acetic acid (1.2 mmol) in the presence of Zncl₂ (0.41 mmol) under microwave irradiation for 20 mins at 200°C. The crude mixture was dissolved in methanol and adsorbed on silica (60-120 #). The desired product was purified by column chromatography with increasing percentage of ethyl acetate in hexane as eluting solvent. The characterization data for the 1-(2-hydroxynaphthalen-1-yl)ethanone is as follows:

Yield: 60 %, mp: 62-68°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 13.48 (1H, s, OH), 8.09 (1H, d, *J* = 8.4 Hz, ArH), 7.89 (1H, d, *J* = 9.0 Hz, ArH), 7.78 (1H, d, *J* = 8.1 Hz, ArH), 7.55-7.60 (1H, m, ArH), 7.37-7.42 (1H, m, ArH), 7.14 (1H, d, *J* = 9.0 Hz, ArH), 2.87 (3H, s, COCH₃). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 35.22, 117.55, 122.59, 126.49, 127.06, 130.85, 131.28,

132.31, 134.63, 140.25, 166.81, 207.44. Anal. Calcd. For C₁₂H₁₀O₂: C, 77.40; H, 5.41; O, 17.18; Found: C, 77.32; H, 5.55.

Procedure for Synthesis of 1-acetylnaphthalen-2-yl benzoate (2)

To a solution of 1-(2-hydroxynaphthalen-1-yl)ethanone (0.01 mol) in pyridine (5 ml), benzoylchloride (1 eq) was added and stirred for 1 hr at room temperature. The mixture was poured on ice and precipitated solid was collected and dried.

Yield: 84 %, mp: 49-53°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 8.19-8.21 (2H, m, ArH), 7.81-7.96 (3H, m, ArH), 7.64-7.67 (1H, m, ArH), 7.53-7.55 (4H, m, ArH), 7.36-7.40 (1H, m, ArH), 2.62 (3H, s, COCH₃); ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 35.01, 124.08, 127.11, 128.84, 130.34, 131.05, 131.33, 131.44, 132.44, 132.95, 133.65, 134.25, 136.76, 147.57, 167.52, 205.70. Anal. Calcd. for C₁₉H₁₄O₃: C, 78.61; H, 4.86; Found: C, 78.93; H, 4.61.

Procedure for Synthesis of 1-(2-hydroxynaphthalen-1-yl)-3-phenylpropane-1,3-dione (3)

The mixture of 1-acetylnaphthalen-2-yl benzoate (0.01 mmol), KOH (1 mmol) and pyridine (2 ml) was warmed on a water bath for 15 mins. Acetic acid solution (10%, 1.3 ml) was added to the cooled mixture. The crude mixture was dissolved in ethyl acetate and adsorbed on silica (60-120 #). The desired product was purified by column chromatography with increasing percentage of ethyl acetate in hexane as eluting solvent. The characterization data for the 1-(2-hydroxynaphthalen-1-yl)-3-phenylpropane-1,3-dione is as follows:

Yield: 65%; ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 11.35 (1H, s, D₂O exchangeable proton), 8.27-8.30 (1H, d, *J* = 8.4 Hz, ArH), 7.90 (1H, s, ArH), 7.67-7.70 (1H, m, ArH), 7.39-7.42 (1H, m, ArH), 7.15-7.26 (5H, m, ArH), 6.66 (1H, s, ArH), 1.29 (2H, s, -CH₂-). Anal. Calcd. for C₁₉H₁₄O₃: C, 78.61; H, 4.86; O, 16.53; Found: C, 78.72; H, 4.73.

Procedure for Synthesis of 5,6-benzoflavones (B-1)

To a solution of the 1-(2-hydroxynaphthalen-1-yl)-3-phenylpropane-1,3-dione (1 mmol) in acetic acid (5 ml) was added a drop of concentrated sulfuric acid and the mixture was refluxed for 1

hour. The cooled mixture was poured into ice and the product was collected by simple filtration. The characterization data for the synthesized derivatives is given below:

3-phenyl-1H-benzo[*f*]chromen-1-one **(B-1)**²²⁻²⁴: Yield 91%, mp 157-162°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 9.78 (1H, d, *J* = 9.0 Hz, ArH), 7.77-7.79 (1H, m, ArH), 7.73-7.74 (1H, m, ArH), 7.56-7.61 (3H, m, ArH), 7.36-7.47 (5H, m, ArH), 6.93 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 108.64, 119.15, 120.43, 122.56, 124.45, 125.32, 126.45, 127.54, 128.32, 129.34, 129.21, 131,65, 131.34, 136.65, 153.34, 162.23, 178.34. MS: m/z: 273 (M⁺+1). Anal. Calcd for C₁₉H₁₂O₂: C, 83.81; H, 4.44; Found: C, 83.59; H, 4.54.

All the 5,6-benzoflavone derivatives were synthesized with above given procedure and their characterization data is given below:

3-(4-methoxyphenyl)-1H-benzo[*f*]**chromen-1-one** (**B-2**)^{22,25}**:** Yield 88%, mp 72-78°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.11 (1H, m, ArH), 8.13-8.17 (3H, m, ArH), 8.07 (1H, m, ArH), 7.97 (1H, m, ArH), 7.41 (2H, d, *J* = 8.5 Hz, ArH), 7.01-7.03 (2H, m, ArH), 6.95 (1H, s, -CH-), 3.96 (3H, s, OCH₃). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 56.93, 108.27, 114.16, 118.45, 119.54, 121.66, 123.45, 123.99, 126.75, 127.16, 128.34, 130.12, 130.67, 135.76, 153.34, 162.56, 177.76. MS: m/z: 303 (M⁺+1). Anal. Calcd for C₂₀H₁₄O₃: C, 79.46; H, 4.67; Found: C, 79.57; H, 4.42.

Published on 19 January 2018. Downloaded by Nagoya Daigaku on 19/01/2018 16:42:03.

3-(3,4-dimethoxyphenyl)-1H-benzo[*f***]chromen-1-one (B-3)**²²: Yield 84%, mp 99-105°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.07 (1H, d, *J* = 8.9 Hz, ArH), 8.12-8.19 (3H, m, ArH), 7.93-7.99 (2H, m, ArH), 7.72-7.78 (3H, m, ArH), 6.94 (1H, s, -CH-), 3.92 (3H, s, OCH₃), 3.96 (3H, s, OCH₃). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 55.83, 56.35, 101.43, 102.99, 1105.54, 107.34, 110.76, 119.45, 122.76, 123.34, 123.76, 123.45, 128.76, 128.34, 129.65, 130.56, 135.34, 148.76, 153.34, 162.54, 177.34. MS: m/z: 322 (M⁺ + 1). Anal. Calcd for C₂₁H₁₆O₄: C, 75.89; H, 4.85; Found: C, 75.91; H, 4.71.

3-(2,4-dimethoxyphenyl)-1H-benzo[*f***]chromen-1-one (B-4)**²⁵: Yield 89%, mp 105-113°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.11 (1H, m, ArH), 8.12-8.14 (3H, m, ArH), 8.06-8.09 (2H, m, ArH), 7.76 (2H, m, ArH), 7.22-7.24 (1H, m, ArH), 7.18 (1H, s, -CH-), 3.94 (3H, s, OCH₃), 3.98 (3H, s, OCH₃). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 55.95, 56.40, 101.34, 102.35, 105.43, 107.22, 119.97, 122.60, 123.74, 123.91, 128.10, 128.44, 128.76, 129.45, 130.66,

135.88, 153.68, 158.75, 160.88, 162.20, 177.33. MS: m/z: 322 (M^+ + 1). Anal. Calcd for $C_{21}H_{16}O_4$: C, 75.89; H, 4.85; Found: C, 75.66; H, 4.91.

3-(3-trifluoromethoxyphenyl)-1H-benzo[*f*]**chromen-1-one (B-5):** Yield 83%, mp: 96-101°C, ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.08 (1H, d, *J* = 8.5 Hz, ArH), 8.14-8.18 (3H, m, ArH), 8.02-8.04 (2H, m, ArH), 7.21-7.26 (2H, m, ArH), 7.09-7.16 (2H, m, ArH), 6.95 (1H, s, -CH-): ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.55, 111.42, 113.67, 118.34, 120.21, 120.65, 122.76, 123.45, 123.65, 128.67, 128.99, 129.54, 129.99, 130.43, 131.78, 135.45, 153.76, 159.34, 162.55, 177.23. MS: m/z: 357 (M⁺ + 1). Anal. Calcd for C₂₀H₁₁F₃O₃: C, 67.42; H, 3.11; F, 16.00; Found C, 67.55; H, 2.99; F, 16.09.

3-(4-trifluoromethoxyphenyl)-1H-benzo[*f*]**chromen-1-one (B-6):** Yield 87%, mp: 115-120°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.09 (1H, d, *J* = 8.6 Hz, ArH), 8.14-8.19 (3H, m, ArH), 8.06-8.09 (2H, m, ArH), 7.88-7.91 (2H, m, ArH), 7.23 (2H, d, *J* = 8.5 Hz, ArH), 6.98 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.76, 115.34, 118.95, 120.76, 120.34, 122.23, 123.21, 123.56, 125.11, 128.17, 128.34, 129.76, 130.45, 135.34, 153.87, 162.45, 177.45. MS: m/z: 357 (M⁺ + 1). Anal. Calcd for C₂₀H₁₁F₃O₃; C, 67.42; H, 3.11; F, 16.00; Found: C, 67.36; H, 3.24; F, 16.01.

3-(2-fluorophenyl)-1H-benzo[*f*]**chromen-1-one** (**B-7**)^{23,24}: Yield 76%, mp 105-109°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.06 (1H, d, *J* = 8.4 Hz, ArH), 8.13 (1H, d, *J* = 9.0 Hz, ArH), 7.91-7.99 (2H, m, ArH), 7.75-7.81 (1H, m, ArH), 7.35-7.66 (5H, m, ArH), 7.13 (1H, s, - CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 115.16, 115.26, 116.90, 117.08, 117.52, 123.78, 124.36, 124.66, 126.71, 127.20, 128.17, 128.90, 129.33, 129.56, 130.41, 130.62, 132.70, 132.77, 135.65, 137.47, 156.40, 157.53, 180.28. MS: m/z: 291 (M⁺ + 1). Anal. calcd. for C₁₉H₁₁FO₂: C, 78.61; H, 3.82; F, 6.54; Found: C, 78.55; H, 3.91; F, 6.44.

3-(3-fluorophenyl)-1H-benzo[*f***]chromen-1-one (B-8):** Yield 78%, mp 123-128°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.03 (1H, d, *J* = 8.6 Hz, ArH), 8.12-8.14 (1H, m, ArH), 7.92-7.95 (2H, m, ArH), 7.75-7.79 (1H, m, ArH), 7.62-7.66 (3H, m, ArH), 7.34-7.36 (2H, m, ArH), 7.14 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 114.13, 115.45, 116.96, 117.56, 117.56, 123.74, 124.33, 124.68, 126.75, 127.27, 128.13, 128.96, 129.34, 129.87, 130.45, 130.34,

132.77, 132.45, 135.67, 137.44, 156.45, 157.56, 180.45. MS: m/z: 291 (M⁺ + 1). Anal. calcd. for C₁₉H₁₁FO₂: C, 78.61; H, 3.82; F, 6.54; Found: C, 78.74; H, 3.75; F, 6.55.

3-(4-fluorophenyl)-1H-benzo[*f***]chromen-1-one (B-9):** Yield 77%, mp 130-136°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.04 (1H, d, *J* = 8.5 Hz, ArH), 8.13-8.15 (1H, m, ArH), 7.91-7.94 (2H, m, ArH), 7.75-7.79 (2H, m, ArH), 7.62-7.66 (2H, m, ArH), 7.22 (2H, d, *J* = 8.9 Hz, ArH), 7.13 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 114.16, 115.43, 116.94, 117.57, 117.54, 123.75, 124.38, 124.64, 126.76, 127.23, 128.16, 128.94, 129.33, 129.84, 130.47, 130.33, 132.72, 132.44, 135.63, 137.45, 156.42, 157.53, 180.42. MS: m/z: 291 (M⁺ + 1). Anal. calcd. for C₁₉H₁₁FO₂: C, 78.61; H, 3.82; F, 6.54; Found: C, 78.72; H, 3.64; F, 6.59.

3-(2,6-difluorophenyl)-1H-benzo[f]chromen-1-one (B-10)^{23,24}: Yield 73%, mp 89-93°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.05 (1H, d, *J* = 8.6 Hz, ArH), 8.13-8.16 (3H, m, ArH), 8.05-8.09 (2H, m, ArH), 7.55-7.58 (1H, m, ArH), 7.23-7.29 (2H, m, ArH), 6.93 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 114.22, 115.46, 116.93, 117.57, 117.53, 123.74, 128.12, 128.64, 129.96, 130.46, 135.34, 153.05, 158.44, 162.26, 179.99. MS: m/z: 309 (M⁺ + 1). Anal. calcd. for C₁₉H₁₀F₂O₂: C, 74.03; H, 3.27; F, 12.33; Found: C, 74.22; H, 3.17; F, 12.44.

Published on 19 January 2018. Downloaded by Nagoya Daigaku on 19/01/2018 16:42:03.

3-(2,4-difluorophenyl)-1H-benzo[*f*]**chromen-1-one (B-11):** Yield 76%, mp 103-108°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.07 (1H, d, *J* = 8.4 Hz, ArH), 8.10-8.15 (3H, m, ArH), 7.99-8.03 (2H, m, ArH), 7.64-7.69 (1H, m, ArH), 7.21-7.25 (2H, m, ArH), 6.91 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 115.21, 115.88, 116.97, 117.53, 117.56, 123.73, 128.17, 128.63, 129.93, 130.47, 135.39, 153.03, 158.47, 162.24, 180.34. MS: m/z: 309 (M⁺ + 1). Anal. calcd. for C₁₉H₁₀F₂O₂: C, 74.03; H, 3.27; F, 12.33; Found: C, 74.22; H, 3.36; F, 12.23.

3-(3,5-difluorophenyl)-1H-benzo[*f*]**chromen-1-one** (**B-12**): Yield 78%, mp 124-139°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 9.80 (1H, d, *J* = 8.4 Hz, ArH), 7.97 (1H, d, *J* = 9.0 Hz, ArH), 7.75 (1H, d, *J* = 8.1 Hz, ArH), 7.42-7.58 (4H, m, ArH), 7.29-7.33 (2H, m, ArH), 6.76-6.85 (1H, m, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 114.56, 115.41, 116.93, 117.54, 117.56, 123.77, 128.18, 128.69, 129.94, 130.43, 135.32, 153.01, 158.42, 162.23, 179.94. MS: m/z: 309 (M⁺ + 1). Anal. calcd. for C₁₉H₁₀F₂O₂: C, 74.03; H, 3.27; F, 12.33; Found: C, 73.99; H, 3.34; F, 12.15.

3-(2,5-difluorophenyl)-1H-benzo[*f*]**chromen-1-one (B-13):** Yield 81%, mp 131-136°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.09 (1H, m, ArH), 8.15-8.19 (3H, m, ArH), 8.02-8.05 (2H, m, ArH), 7.33-7.42 (3H, m, ArH), 6.85 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 106.64, 109.09, 109.31, 111.43, 117.36, 126.90, 127.11, 128.24, 129.49, 130.33, 130.71, 135.96, 137.01, 157.27, 162.43, 164.31, 179.84. MS: m/z: 309 (M⁺ + 1). Anal. calcd. for C₁₉H₁₀F₂O₂: C, 74.03; H, 3.27; F, 12.33; Found: C, 74.21; H, 3.08; F, 12.66.

3-(3,4-difluorophenyl)-1H-benzo[*f*]chromen-1-one (B-14): Yield 79%, mp 104-107°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.06 (1H, m, ArH), 8.12-8.17 (3H, m, ArH), 8.02-8.05 (2H, m, ArH), 7.42-7.45 (1H, m, ArH), 7.38 (1H, s, ArH), 7.29-7.32 (1H, m, ArH), 6.94 (1H, s, - CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 115.23, 115.65, 116.96, 117.53, 117.55, 123.71, 128.16, 128.67, 129.93, 130.42, 135.37, 153.08, 158.41, 162.23, 179.95. MS: m/z: 309 (M⁺ + 1). Anal. calcd. for C₁₉H₁₀F₂O₂: C, 74.03; H, 3.27; F, 12.33; Found: C, 74.32; H, 3.45; F, 12.10.

3-(3-chlorophenyl)-1H-benzo[*f***]chromen-1-one (B-15):** Yield 78%, mp 160-166°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.07 (1H, m, ArH), 8.11-8.17 (3H, m, ArH), 8.00-8.04 (2H, m, ArH), 7.66 (1H, s, ArH), 7.23-7.30 (3H, m, ArH), 6.96 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 115.45, 117.45, 117.65, 126.26, 127.64, 128.36, 129.08, 130.33, 131.64, 132.37, 133.35, 134.34, 135.43, 136.55, 153.54, 161.18, 180.05. MS: m/z: 307 (M⁺ + 1). Anal. calcd. for C₁₉H₁₁ClO₂: C, 74.40; H, 3.61; Cl, 11.56; Found: C, 74.50; H, 3.59; Cl, 11.60.

3-(2,3-dichlorophenyl)-1H-benzo[*f***]chromen-1-one (B-16):** Yield 84%, mp 160-165°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.08 (1H, m, ArH), 8.15-8.19 (3H, m, ArH), 7.98-8.03 (2H, m, ArH), 7.32-7.36 (3H, m, ArH), 6.81 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 115.97, 117.26, 117.55, 126.80, 127.16, 127.64, 128.21, 129.02, 129.40, 130.41, 130.69, 131.67, 132.51, 133.71, 134.61, 135.83, 157.79, 159.70, 179.79. MS: m/z: 341 (M⁺ + 1). Anal. calcd. for C₁₉H₁₀Cl₂O₂: C, 66.89; H, 2.95; Cl, 20.78; Found: C, 66.99; H, 2.85; Cl, 20.91.

3-(2-bromophenyl)-1H-benzo[*f***]chromen-1-one (B-17):** Yield 75%, mp 153-159°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.08 (1H, d, *J* = 8.7 Hz, ArH), 8.13 (1H, d, *J* = 9.0 Hz, ArH), 7.94 (1H, *d*, *J* = 7.5 Hz, ArH), 7.40-7.80 (7H, m, ArH), 6.78 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 115.12, 116.89, 117.07, 117.11, 117.51, 119.90, 124.64, 124.66, 126.71, 127.19, 128.18, 128.90, 129.33, 130.61, 132.71, 132.79, 135.68, 157.54, 180.32. MS: m/z: 350

 $(M^+ + 1)$. Anal. calcd. for $C_{19}H_{11}BrO_2$: C, 64.98; H, 3.16; Br, 22.75; Found: C, 65.05; H, 3.03; Br, 22.88.

3-(3-bromophenyl)-1H-benzo[*f***]chromen-1-one (B-18):** Yield 78%, mp 168-171°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.04 (1H, d), 8.15 (1H, d, *J* = 9.0 Hz, ArH), 7.95 (1H, m, ArH), 7.77-7.83 (3H, m, ArH), 7.63 (1H, s, ArH), 7.23-7.33 (3H, m ArH), 6.98 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 110.53, 117.23, 117.43, 126.08, 126.79, 127.18, 127.47, 128.16, 129.35, 130.34, 130.42, 130.67, 132.35, 135.66, 157.33, 159.72, 179.97. MS: m/z: 350 (M⁺ + 1). Anal. calcd. for C₁₉H₁₁BrO₂: C, 64.98; H, 3.16; Br, 22.75; Found: C, 65.02; H, 3.09; Br, 22.79.

3-(4-bromophenyl)-1H-benzo[*f***]chromen-1-one (B-19):** Yield 80%, mp 220-225°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.06 (1H, d, *J* = 8.7 Hz, ArH), 8.14 (1H, d, *J* = 9.0 Hz, ArH), 7.93 (1H, d, J = 8.1 Hz, ArH), 7.78-7.85 (3H, m, ArH), 7.61-7.70 (4H, m, ArH), 6.97 (1H, s, - CH-). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 110.57, 117.28, 117.46, 126.05, 126.74, 127.16, 127.49, 128.18, 129.34, 130.34, 130.43, 130.65, 132.37, 135.65, 157.32, 159.76, 180.07. MS: m/z: 350 (M⁺+1). Anal. calcd. for C₁₉H₁₁BrO₂: C, 64.98; H, 3.16; Br, 22.75; Found: C, 64.78; H, 3.00; Br, 22.65.

3-(2-iodophenyl)-1H-benzo[*f***]chromen-1-one (B-20):** Yield 69%, mp 141-146°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.05 (1H, m, ArH), 8.19-8.25 (3H, m, ArH), 8.11-8.13 (2H, m, ArH), 7.82-7.84 (1H, m, ArH), 7.31-7.36 (3H, m, ArH), 6.96 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 110.32, 113.65, 119.25, 120.65, 122.82, 124.16, 125.62, 127.26, 128.12, 128.56, 129.47, 130.81, 131.94, 136.03, 138.07, 140.53, 154.02, 165.25, 180.12. MS: m/z: 398 (M⁺ + 1). Anal. calcd. for C₁₉H₁₁IO₂: C, 57.31; H, 2.78; I, 31.87; Found: C, 57.42; H, 2.88; I, 31.93.

3-(4-iodophenyl)-1H-benzo[*f***]chromen-1-one (B-21):** Yield 72%, mp 133-139°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.08 (1H, m, ArH), 8.19-8.25 (3H, m, ArH), 8.11-8.13 (2H, m, ArH), 7.88 (2H, d, *J* = 8.9 Hz, ArH), 7.25-7.29 (2H, m, ArH), 6.95 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 110.55, 113.69, 119.28, 120.62, 122.87, 124.13, 125.67, 127.22, 128.16, 128.53, 129.42, 130.87, 131.92, 136.34, 138.09, 140.51, 154.07, 165.29, 180.18. MS:

m/z: 398 (M⁺ + 1). Anal. calcd. for $C_{19}H_{11}IO_2$: C, 57.31; H, 2.78; I, 31.87; Found: C, 57.28; H, 2.79; I, 31.77.

3-(3-nitrophenyl)-1H-benzo[f]chromen-1-one (B-22): Yield 79%, mp 139-141°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.15 (1H, m, ArH), 8.42 (1H, m, ArH), 8.11-8.14 (3H, m, ArH), 7.78-7.85 (2H, m, ArH), 7.62-7.65 (2H, m, ArH), 7.07 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 112.48, 115.93, 117.35, 124.25, 124.30, 126.77, 126.99, 127.14, 128.20, 128.31, 129.31, 129.62, 136.14, 136.16, 137.45, 157.45, 158.11, 179.74. MS: m/z: 318 (M⁺ + 1). Anal. calcd. for C₁₉H₁₁NO₄: C, 71.92; H, 3.49; N, 4.41; Found: C, 72.00; H, 3.33; N, 4.34.

3-(4-nitrophenyl)-1H-benzo[*f*]**chromen-1-one (B-23):** Yield 76%, mp: 102-106°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.14 (1H, d, *J* = 8.4 Hz, ArH), 8.41 (1H, d, *J* = 8.7 Hz, ArH), 8.14-8.19 (3H, m, ArH), 7.95 (1H, d, *J* = 8.4 Hz, ArH), 7.78-7.80 (1H, m, ArH), 7.65-7.68 (2H, m, ArH), 7.08 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 112.48, 115.93, 117.35, 124.25, 124.30, 126.77, 126.99, 127.14, 128.20, 128.31, 129.31, 129.62, 136.14, 136.16, 137.45, 157.45, 158.11, 179.74. MS: m/z: 318 (M⁺ + 1). Anal. calcd. for C₁₉H₁₁NO₄: C, 71.92; H, 3.49; N, 4.41; Found: C, 71.85; H, 3.35; N, 4.65.

3-(3,5-dinitrophenyl)-1H-benzo[*f*]chromen-1-one (B-24): Yield 81%, mp 101-106°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.15 (1H, s, ArH), 9.08 (1H, s, ArH), 8.65-8.70 (2H, m, ArH), 8.11 (1H, m, ArH), 7.97-7.99 (1H, m, ArH), 7.77-7.84 (3H, m, ArH), 7.07 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 112.43, 115.97, 117.39, 124.22, 124.36, 126.73, 126.93, 127.17, 128.24, 128.36, 129.37, 129.67, 136.18, 136.13, 137.46, 157.47, 158.18, 180.75 MS: m/z: 363 (M⁺+1). Anal. calcd. for C₁₉H₁₀N₂O₆: C, 62.76; H, 2.93; N, 7.35; Found: C, 62.66; H, 3.03; N, 7.30.

3-*p*-tolyl-1H-benzo[*f*]chromen-1-one (B-25)²⁴: Yield 85%, mp: 96-102°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.04 (1H, m, ArH), 8.12-8.18 (3H, m, ArH), 8.01-8.06 (2H, m, ArH), 7.33 (2H, d, *J* = 8.4 Hz, ArH), 7.11-7.15 (2H, m, ArH), 7.01 (1H, s, -CH-), 2.45 (3H, s, -CH₃). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 26.45, 110.26, 119.93, 122.65, 123.77, 123.95, 126.33, 127.46, 128.18, 128.63, 129.07, 129.93, 130.45, 135.32, 138.55, 153.04, 162.25, 180.24. MS: m/z: 287 (M⁺+1). Anal. calcd. for C₂₀H₁₄O₂: C, 83.90; H, 4.93; Found: C, 83.80; H, 4.98.

3-(4-(trifluoromethyl)phenyl)-1H-benzo[f]chromen-1-one (B-26): Yield 85%, mp: 115-119°C, ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.04 (1H, m, ArH), 8.14-8.19 (3H, m, ArH), 8.01-8.05 (2H, m, ArH), 7.88 (2H, d, *J* = 8.9 Hz, ArH), 7.41-7.45 (2H, m, ArH) 6.97 (1H, s, - CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.221, 119.91, 122.62, 123.73, 123.95, 126.52, 128.12, 128.64, 129.93, 130.25, 130.46, 133.57, 135.31, 153.03, 162.22, 177.25. MS: m/z: 341 (M⁺+1). Anal. calcd. for C₂₀H₁₁F₃O₂: C, 70.59; H, 3.26; F, 16.75; Found: C, 70.68; H, 3.06; F, 16.82.

3-(3-(trifluoromethyl)phenyl)-1H-benzo[*f*]**chromen-1-one (B-27):** Yield 74%, mp 106-110°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.07 (1H, m, ArH), 8.13-8.17 (3H, m ArH), 8.00-8.04 (2H, m, ArH), 7.88 (1H, s, ArH), 7.21-7.33 (3H, m, ArH), 6.97 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 111.45, 119.95, 122.66, 122.83, 123.76, 123.93, 124.05, 124.67, 128.17, 128.67, 129.74, 129.93, 130.45, 130.76, 130.92, 135.33, 153.05, 162.26, 180.28. MS: m/z: 341 (M⁺+1). Anal. calcd. for C₂₀H₁₁F₃O₂: C, 70.59; H, 3.26; F, 16.75; Found: C, 70.49; H, 3.35; F, 16.65.

Published on 19 January 2018. Downloaded by Nagoya Daigaku on 19/01/2018 16:42:03.

3-(2-(trifluoromethyl)phenyl)-1H-benzo[f]chromen-1-one (B-28): Yield: 81%; mp 105-108°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.06 (1H, m, ArH), 8.11-8.14 (3H, m, ArH), 8.00-8.04 (2H, m, ArH), 7.88-7.91 (1H, m, ArH), 7.21-7.33 (3H, m, ArH), 6.97 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.45, 119.94, 122.63, 122.85, 123.76, 123.96, 124.05, 124.64, 128.13, 128.62, 129.71, 129.92, 130.43, 130.74, 130.95, 135.36, 153.07, 162.28, 180.29. MS: m/z: 341 (M⁺+1). Anal. calcd. for C₂₀H₁₁F₃O₂: C, 70.59; H, 3.26; F, 16.75; Found: C, 70.48; H, 3.35; F, 16.38.

3-(3-(trifluoromethyl)phenyl)-1H-benzo[/]chromen-1-one (B-29): Yield 80%, mp 96-101°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.09 (1H, m, ArH), 8.13-8.18 (3H, m, ArH), 7.97-8.02 (2H, m, ArH), 7.84 (1H, s, ArH), 7.41-7.53 (3H, m, ArH), 6.93 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.48, 119.98, 122.67, 122.86, 123.75, 123.94, 124.03, 124.62, 128.12, 128.61, 129.74, 129.95, 130.46, 130.77, 130.94, 135.33, 153.06, 162.23, 180.25. MS: m/z: 409 (M⁺+1). Anal. calcd. for C₂₁H₁₀F₆O₂: C, 61.78; H, 2.47; F, 27.92; Found: C, 61.68; H, 2.55; F, 27.83.

3-(4-fluoro-2-(trifluoromethyl)phenyl)-1H-benzo[*f*]**chromen-1-one (B-30):** Yield 81%, mp 155-159°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.06 (1H, d, *J* = 8.6 Hz, ArH), 8.13-8.16 (3H, m, ArH), 8.06 (1H, m, ArH), 8.01 (1H, m, ArH), 7.64-7.66 (1H, m, ArH), 7.44-7.47 (1H, m, ArH), 7.23 (1H, m, ArH), 6.86 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.65, 110.99, 114.75, 117.47, 119.99, 121.45, 122.69, 123.74, 123.96, 125.94, 126.63, 128.17, 128.67, 129.94, 130.47, 135.34, 153.05, 162.25, 164.55, 180.42. MS: m/z: 359 (M⁺+1). Anal. calcd. for C₂₀H₁₀F₄O₂: C, 67.05; H, 2.81; F, 21.21; Found: C, 67.11; H, 2.79; F, 21.33.

3-(2-fluoro-4-(trifluoromethyl)phenyl)-1H-benzo[*f*]**chromen-1-one (B-31):** Yield 82%, mp 151-155°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.08 (1H, d, *J* = 8.6 Hz, ArH), 8.14-8.17 (3H, m, ArH), 8.03-8.06 (2H, m, ArH), 7.22-7.43 (3H, m, ArH), 6.85 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.23, 110.67, 114.74, 117.45, 119.67, 121.65, 122.76, 123.34, 123.78, 125.45, 126.67, 128.45, 128.89, 129.45, 130.67, 135.67, 153.65, 162.67, 164.56, 180.56. MS: m/z: 359 (M⁺ +1). Anal. calcd. for C₂₀H₁₀F₄O₂: C, 67.05; H, 2.81; F, 21.21; Found: C, 67.12; H, 2.76; F, 21.34.

3-(2-fluoro-6-(trifluoromethyl)phenyl)-1H-benzo[*f***]chromen-1-one (B-32):** Yield 73%, mp 122-127°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.07 (1H, d, *J* = 8.6 Hz, ArH), 8.12-8.14 (3H, m, ArH), 8.02-8.06 (2H, m, ArH), 7.19-7.28 (3H, m, ArH), 6.86 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.64, 110.93, 114.74, 117.45, 119.93, 121.45, 122.66, 123.74, 123.93, 125.92, 126.65, 128.14, 128.64, 129.93, 130.44, 135.36, 153.04, 162.27, 164.54, 180.47. MS: m/z: 359 (M⁺+1). Anal. calcd. for C₂₀H₁₀F₄O₂: C, 67.05; H, 2.81; F, 21.21; Found: C, 67.22; H, 2.76; F, 21.32.

3-(5-fluoro-2-(trifluoromethyl)phenyl)-1H-benzo[/]chromen-1-one (B-33): Yield 74%, mp 144-147°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.05 (1H, m, ArH), 8.10-8.13 (3H, m, ArH), 8.02-8.05 (2H, m, ArH), 7.74-7.78 (1H, m, ArH), 7.11-7.23 (2H, m, ArH), 6.85 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.62, 110.92, 114.73, 117.49, 119.98, 121.48, 122.69, 123.78, 123.97, 125.96, 126.68, 128.16, 128.67, 129.95, 130.46, 135.34, 153.07, 162.25, 164.56, 180.43. MS: m/z: 359 (M⁺+1). Anal. calcd. for C₂₀H₁₀F₄O₂: C, 67.05; H, 2.81; F, 21.21; Found: C, 67.25; H, 2.65; F, 21.54.

3-(3-fluoro-5-(trifluoromethyl)phenyl)-1H-benzo[*f***]chromen-1-one (B-34):** Yield 69%, mp 110-115°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.11 (1H, m, ArH), 8.14-8.19 (3H, m, ArH), 8.02-8.00 (2H, m, ArH), 7.66 (1H, s, ArH), 7.21 (2H, m, ArH), 6.94 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.67, 110.95, 114.45, 117.78, 119.45, 121.98, 122.45, 123.67, 123.76, 125.54, 126.67, 128.54, 128.89, 129.43, 130.54, 135.55, 153.43, 162.54, 164.34, 180.23. MS: m/z: 359 (M⁺+1). Anal. calcd. for C₂₀H₁₀F₄O₂: C, 67.05; H, 2.81; F, 21.21; Found: C, 67.14; H, 2.74; F, 21.45.

3-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-benzo[*f***]chromen-1-one (B-35):** Yield 81%, mp 158-164°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.10 (1H, m, ArH), 8.16-8.20 (3H, m, ArH), 8.04-8.08 (2H, m, ArH), 7.69 (1H, s, ArH), 7.44 (1H, d, *J* = 8.9 Hz, ArH), 7.23-7.25 (1H, m, ArH), 6.96 (1H, s, -CH-). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 110.64, 110.93, 114.74, 117.45, 119.93, 121.45, 122.66, 123.74, 123.93, 125.92, 126.65, 128.14, 128.64, 129.93, 130.44, 135.36, 153.04, 162.27, 164.54, 180.47. MS: m/z: 359 (M⁺+1). Anal. calcd. for C₂₀H₁₀F₄O₂: C, 67.05; H, 2.81; F, 21.21; Found: C, 67.21; H, 2.66; F, 21.29.

3-(4-(chloromethyl)phenyl)-1H-benzo[*f*]**chromen-1-one (B-36):** Yield 74%, mp 116-120°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.05 (1H, m, ArH), 8.11-8.15 (3H, m, ArH), 8.05-8.07 (2H, m, ArH), 7.66 (2H, d, *J* = 8.6 Hz, ArH), 7.29 (2H, d, *J* = 8.6 Hz, ArH), 6.98 (1H, s, -CH-), 4.64 (2H, s, CH₂Cl). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 48.54, 110.56, 119.87, 122.45, 123.34, 123.78, 125.56, 128.45, 128.76, 128.99, 129.45, 130.43, 130.55, 135.67, 137.34, 153.56, 162.56, 180.34. MS: m/z: 321 (M⁺+1). Anal. calcd. for C₂₀H₁₃ClO₂: C, 74.89; H, 4.08; Cl, 11.05; Found: C, 74.79; H, 4.18; Cl, 11.25.

3-(3-(chloromethyl)phenyl)-1H-benzo[f]chromen-1-one (B-37): Yield 77%, mp 101-105°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.11 (1H, m, ArH), 8.14-8.17 (3H, m, ArH), 8.06-8.09 (2H, m, ArH), 7.33-7.49 (3H, m, ArH), 6.98 (1H, s, -CH-), 4.69 (2H, s, CH₂Cl). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 48.23, 110.23, 119.45, 122.45, 123.65, 123.45, 125.65, 128.54, 128.34, 128.34, 129.45, 130.56, 130.45, 135.23, 137.56, 153.34, 162.23, 180.45. MS: m/z: 321 (M⁺+1). Anal. calcd. for C₂₀H₁₃ClO₂: C, 74.89; H, 4.08; Cl, 11.05; Found: C, 74.78; H, 4.24; Cl, 10.96.

3-(4-(dimethylamino)phenyl)-1H-benzo[*f***]chromen-1-one (B-38):** Yield 74%, mp 100-105°C. ¹H NMR (CDCl₃, 300 MHz, δ , TMS = 0): 10.04 (1H, m, ArH), 8.14-8.17 (3H, m, ArH), 8.05-8.07 (2H, m, ArH), 7.41 (2H, d, *J* = 8.7 Hz, ArH), 7.22-7.25 (2H, m, ArH), 6.99 (1H, s, -CH-), 2.89 (3H, s, N(CH₃)₂), 2.83 (3H, s, N(CH₃)₂). ¹³C NMR (CDCl₃, 75 MHz, δ , TMS = 0): 42.56, 42.78, 110.56, 114.34, 119.54, 119.89, 122.65, 123.45, 123.67, 127.45, 128.34, 128.69, 129.56, 130.45, 135.67, 147.54, 153.56, 162.24, 180.56. MS: m/z: 316 (M⁺+1). Anal. calcd. for C₂₁H₁₇NO₂: C, 79.98; H, 5.43; N, 4.44; Found: C, 79.86; H, 5.66; N, 4.34.

3-(3-(acetoxy)phenyl)-1H-benzo[*f***]chromen-1-one (B-39):** Yield 78%, mp 160-165°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.11 (1H, m, ArH), 8.14-8.18 (3H, m, ArH), 8.03-8.05 (2H, m, ArH), 7.77-7.82 (2H, m, ArH), 7.33-7.35 (2H, m, ArH), 6.94 (1H, s, -CH-), 2.16 (3H, s, OCOCH₃). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 23.34, 110.65, 119.45, 121.46, 121.84, 122.65, 123.74, 123.92, 126.76, 127.56, 128.16, 128.66, 129.97, 130.47, 135.37, 153.08, 162.28, 168.75, 180.32. MS: m/z: 331 (M⁺+1). Anal. calcd. for C₂₁H₁₄O₄: C, 76.35; H, 4.27; Found: C, 76.29; H, 4.34.

3-(4-(acetoxy)phenyl)-1H-benzo[f]chromen-1-one (B-40): Yield 81%, mp 159-163°C. ¹H NMR (CDCl₃, 300 MHz, δ, TMS = 0): 10.10 (1H, m, ArH), 8.14-8.18 (3H, m, ArH), 8.02-8.04 (2H, m, ArH), 7.66 (2H, d, *J* = 8.5 Hz, ArH), 7.13-7.15 (2H, m, ArH), 6.96 (1H, s, -CH-), 2.14 (3H, s, OCOCH₃). ¹³C NMR (CDCl₃, 75 MHz, δ, TMS = 0): 23.54, 110.25, 119.96, 121.48, 121.86, 122.67, 123.74, 123.95, 126.73, 127.66, 128.14, 128.62, 129.93, 130.42, 135.35, 153.02, 162.22, 168.75, 179.99. MS: m/z: 331 (M⁺+1). Anal. calcd. for C₂₁H₁₄O₄: C, 76.35; H, 4.27; Found: C, 76.42 H, 4.18.

In vitro cholesterol esterase assay

Porcine cholesterol esterase inhibition was assayed spectrophotometrically at 405 nm at 25 °C. Assay buffer was 100 mM sodium phosphate, 100 mM NaCl, pH 7.0. A stock solution of CEase (200 μ g/mL) was prepared in 100 mM sodium phosphate buffer, pH 7.0 and kept at 0 °C. A 1:200 dilution was done with the same buffer immediately before starting the measurement. Sodium taurocholate (12 mM) was dissolved in assay buffer and kept at 25 °C. A stock solution of paranitrophenyl butyrate (20 mM) was prepared in acetonitrile. The final concentration of acetonitrile was 3%, of the substrate para-nitrophenyl butyrate 20 μ M, and of sodium taurocholate 6 mM. Assays were performed with a final concentration of 10 ng/mL of CEase.

Into a cuvette containing 430 μ L assay buffer, 500 μ L of the sodium taurocholate solution, 20 μ L acetonitrile, 10 μ L of the para-nitrophenyl butyrate solution, and 30 μ L of an inhibitor solution in DMSO were added and thoroughly mixed. After incubation for 5 min at 25°C, the reaction was initiated by adding 10 μ L of the enzyme solution 1 μ g/mL. All the experiments were performed in triplicate and values were expressed as means of three experiments.⁸

Enzyme kinetics study

Synthesized compounds were further investigated for the type of inhibition and enzyme kinetics study were carried out. The Lineweaver-Burk plot will be established from which we can calculate the K_m , V_{max} of the slope of inhibitor and the value of α (a constant that defines the degree to which inhibitor binding affects the affinity of the enzyme for substrate).¹⁹

Docking study

Published on 19 January 2018. Downloaded by Nagoya Daigaku on 19/01/2018 16:42:03.

To study the binding mode of the synthesized compounds, we have docked the most potent compound **B-16** at the catalytic site of lipase. The X-ray coordinates of catalytic domain of human bile salt activated lipase (*h*BAL, *h*CEase) was obtained from protein data bank (PDB entry: 1F6W; Resolution 2.3Å).²⁰ The docking study was carried out using GOLD v5.3 software.²⁶ Gold performs genetic algorithm based ligand docking to optimize the conformation of ligand at the receptor binding site. The Goldscore fitness function was used to evaluate the various conformations of ligand at the binding site. Goldscore comprises of four components: protein–ligand hydrogen bond energy, protein–ligand van der Waals (vdw) energy, ligand internal vdw energy and ligand torsional strain energy.²⁶ **B-16** was docked ten times and conformation associated with highest scoring value was considered to analyze various drug-receptor interactions. The Structure of **B-16** was drawn in ChemDraw Ultra (2010) and subjected to energy minimization using the MM2 force field as implemented in Chem 3D Ultra software.

Conflict of interest

The authors declare no competing interests.

Acknowledgement

Authors are grateful to University Grants Commission for providing funds under university with potential for excellence (UPE) Scheme and Rajiv Gandhi National Fellowship (RGNF) to carry out the research work. The authors are also thankful to Dr. Sahil Sharma, Research Fellow, Memorial Sloan Kettering Cancer Center, New York, USA for his valuable support and guidance.

Captions

Figure 1. Reported CEase inhibitors¹⁸

Scheme 1. Synthesis of 5,6-benzoflavone. Reagents and conditions: (a) MW, ZnCl₂, CH₃COOH, 20 min; (b) benzoyl chloride, pyridine, stirring rt, 1 h; (c) KOH, pyridine, warm, 15 min; (d) a drop of conc. H₂SO₄, CH₃COOH, reflux, 30 min.

Figure 2. Design strategy for target compounds

Figure 3. Structure Activity Relationship

Figure 4. Lineweaver-Burk plot of B-16

Figure 5. Schematic 2D representations of *h*Cease-**B-16** complex showing H-bond and van der Walls interactions (Figure generated by LIGPLOT²⁷)

Figure 6. Docked conformation of B-16 at the catalytic site of hCEase (B-16: carbon atoms are shown in green; only hydrogens which are involved in H-bond interactions are shown in white color)

Figure 7. Docked conformation of B-16 and A (lead compound) at the catalytic site of hCEase

(B-16: shown in green; A: shown in purple)

Table 1. Various substituted 5,6-Benzoflavone derivatives and their CEase inhibitory activity

 Table 2. In silico ADME properties of 5,6-Benzoflavone derivatives

 Table 3. Physicochemical parameters of 5,6-Benzoflavone derivatives

REFERENCES

- 1. R. Mahalwar and D. Khanna, Eur. J. Pharmacol., 2013, 711, 57-62.
- S. Heng, W. Tieu, S. Hautmann, K. Kuan, D. S. Pedersen, M. Pietsch, M. Gutschow and A. D. Abell, *Bioorg. Med. Chem.*, 2011, 19, 7453-7463.
- 3. M. Pietsch and M. Gutschow, J. Med. Chem., 2005, 48, 8270-8288 (and the references therein).
- 4. (a) G. B. Quistad, S. N. Liang, K. J. Fisher, D. K. Nomura and J. E Casida, *Toxicol. Sci.*, 2006, 91, 166-175; (b) H. Schmidinger, R. Birner-Gruenberger, G. Riesenhuber, R. Saf, E. H. Susani and A. Hermetter, *Chem. Bio. Chem.*, 2005, 6, 1776-1781.
- (a) M. C. Lin, G. Z. Lin, C. I. Hwang, S. Y. Jian, J. Lin, Y. F. Shen and G. Lin, *Protein Sci.*, 2012, 21, 1344-1357; (b) M. C. Lin, S. J. Yeh, I. R. Chen and G. Lin, *Protein J.*, 2011, 30, 220-227; (c) S. Y. Chiou, C. Y. Lai, L. Y. Lin and G. Lin, *BMC Biochem*. 2005, 6, 17; (d) G. Lin, W. C. Liao and S. Y. Chiou, *Bioorg. Med. Chem.*, 2000, 8, 2601-2607; (e) G. Lin, C. T. Shieh, Y. C. Tsai, C. I. Hwang, C. P. Lu and G. H. Cheng, *Biochim. Biophys. Acta*, 1999, 1431, 500-511; (f) S.R. Feaster, K. Lee, N. Baker, D. Y. Hui and D. M. Quinn, *Biochemistry*, 1996, 35, 16723-16734.
- J. J. Heynekamp, L. A. Hunsaker, J. T. A. Vander, R. E. Royer, L. M. Deck and J. D. L. Vander, *Bioorg. Med. Chem.*, 2008, 16, 5285-5294.
- H. M. Stoddard, W. M. Brown, J. A. Deck, L. A. Hunsaker, L. M. Deck and J. D. L. Vander, *Biochim. Biophys. Acta.*, 2002, 596, 381-391.
- G. C. Muscia, S. Hautmann, G. Y. Buldain and M. Gutschow, *Bioorg. Med. Chem. Lett.*, 2014, 24, 1545-1549.
- V. Point, A. Benarouche, J. Zarillo, A. Guy, R. Magnez, L. Fonseca, B. Raux, J. Leclaire, G. Buono, F. Fotiadu, T. Durand, F. Carriere, C. Vaysse, L. Couedelo and J. F. Cavalier, *Eur. J. Med. Chem.*, 2012, 58, 452-463.
- 10. B. Li, B. Zhou, H. Lu, L. Ma and A. Y. Peng, Eur. J. Med. Chem., 2010, 45, 1955-1963.
- Y. Wei, A. Y. Peng, B. Wang, L. Ma, G. Peng, Y. Du, J. Tang, *Eur. J. Med. Chem.*, 2014, 74, 751-758.
- 12. M. Pietsch and M. Gutschow, J. Biol. Chem., 2002, 277, 24006-24013.

- 13. L. M. Deck, M. L. Baca, S. L. Salas, L. A. Hunsaker and D. L. Vander-Jagt, *J. Med. Chem.*, 1999, 42, 4250-4256.
- 14. G. Lin, S. Y. Chiou, B. C. Hwu and C. W. Hsieh, Protein J., 2006, 25, 33-43.
- 15. G. Lin, C. T. Shieh, H. C. Ho, J. Y. Chouhwang, W. Y. Lin and C. P. Lu, *Biochemistry*, 1999, 38, 9971-9981.
- G. Lin, Y. Tsai, H. C. Liu, W. C. Liao and C. H. Chang, *Biochim. Biophys. Acta.*, 1998, 1388, 161-174.
- 17. M. Cygler, J. D. Schrag, J. L. Sussman, M. Harel, I. Silman, M. K. Gentry, B. P. Doctor, *Protein Sci.*, 1993, 2, 366-382.
- H. Singh, J. V. Singh, M. K. Gupta, P. Singh, S. Sharma, K. Nepali and P. M. S. Bedi, *Bioorg. Med. Chem. Lett.*, 2017, 27, 850-854.
- 19. M. Singh, M. Kaur and O. Silakari, Eur. J. Med. Chem., 2014, 84, 206-239.
- S. Terzyan, C. S. Wang, D. Downs, B. Hunter and X. C. Zhang, *Protein Sci.*, 2000, 9, 1783-1790.
- 21. S. John, S. Thangapandian and K. W. J. Lee, Biomol. Struct. Dyn., 2012, 29, 921-936.
- 22. K. Juvale, K. Stefan and M. Wiese, Eur. J. Med. Chem., 2013, 67, 115-126.
- 23. Y. Fujita, M. Yonehara, M. Tetsuhashi, T. Noguchi-Yachide, Y. Hashimoto and M. Ishikawa, *Bioorg. Med. Chem.*, 2010, **18**, 1194–1203.
- 24. Y. Fujita, M. Yonehara, K. Kitahara, J. Shimokawa, Y. Hashimoto and M. Ishikawa, *Heterocycles.*, 2011, **83**, 2563-2575.
- D. Hwang, G. Jo, J. Hyun, S. D. Lee, D. Kohc and Y. Lima, *Magn. Reson. Chem.*, 2012, 50, 62-67.
- 26. GOLD v5.3. Cambridge Crystallographic Data Centre: Cambridge, U.K. 2015.
- 27. A. C. Wallace, R. A. Laskowski, J. M. Thornton, Protein Eng., 1995, 8, 127-34.

MedChemComm

Page 24 of 35 View Article Online DOI: 10.1039/C7MD00565B







Figure 1. Reported CEase inhibitors¹⁸







2-(1H-Indol-3-yl)-4-phenylquinolines



Scheme 1. Synthesis of 5,6-benzoflavones. Reagents and conditions: (a) MW, $ZnCl_2$, CH₃COOH, 20 min; (b) benzoyl chloride, pyridine, stirring rt, 1 h; (c) KOH, pyridine, warm, 15 min; (d) a drop of conc. H₂SO₄, CH₃COOH, reflux, 30 min.








Figure 3. Structure Activity Relationship

MedChemComm

MedChemComm Accepted Manuscript




Figure 4. Lineweaver-Burk plot of B-16




Figure 5. Schematic 2D representations of *h*CEase-**B-16** complex showing H-bond and van der Waals interactions (Figure generated by LIGPLOT²⁷)




Figure 6. Docked conformation of B-16 at the catalytic site of *h*CEase (B-16: carbon atoms are shown in green; only hydrogens which are involved in H-bond interactions are shown)





Figure 7. Docked conformation of **B-16** and **A** (lead compound) at the catalytic site of *h*CEase (**B-16**: shown in green; **A**: shown in purple)

Table 1. Various substituted 5,6-Benzoflavone derivatives and their CEase inhibitory activity



Code	R ₁	R ₂	R ₃	R ₄	R ₅	$IC_{50} (nM \pm SD)$
B-1	Н	Н	Н	Н	Н	51.06 ± 2.33
B-2	Н	Н	OCH ₃	Н	Н	ND
В-3	Н	OCH ₃	OCH ₃	Н	Н	ND
B -4	OCH ₃	Н	OCH ₃	Н	Н	ND
В-5	Н	OCF ₃	Н	Н	Н	ND
В-6	Н	Н	OCF ₃	Н	Н	ND
B-7	F	Н	Н	Н	Н	2.59 ± 0.33
B-8	Н	F	Н	Н	Н	3.90 ± 0.43
B-9	Н	Н	F	Н	Н	4.50 ± 0.54
B-10	F	Н	Н	Н	F	1.19 ± 0.24
B-11	F	Н	F	Н	Н	1.46 ± 0.34
B-12	Н	F	Н	F	Н	0.99 ± 0.17
B-13	F	Н	Н	F	Н	1.08 ± 0.19
B-14	Н	F	F	Н	Н	1.15 ± 0.23
B-15	Н	Cl	Н	Н	Н	0.83 ± 0.14
B-16	Cl	Cl	Н	Н	Hview Article Online	0.73 ± 0.09
B-17	Br	Н	Н	Н	DOI: 10.1039/C7MD00565B	4.69 ± 0.76
B-18	Н	Br	Н	Н	Н	6.01 ± 0.54
B-19	Н	Н	Br	Н	Н	8.15 ± 0.56
B-20	Ι	Н	Н	Н	Н	9.55 ± 0.67
B-21	Н	Н	Ι	Н	Н	13.11 ± 0.56
B-22	Н	NO ₂	Н	Н	Н	16.44 ± 0.76
B-23	Н	Н	NO ₂	Н	Н	18.01 ± 0.65
B-24	Н	NO ₂	Н	NO ₂	Н	9.80 ± 0.53
B-25	Н	Н	CH ₃	Н	Н	ND
B-26	Н	Н	CF ₃	Н	Н	ND
B-27	Н	CF ₃	Н	Н	Н	ND
B-28	CF ₃	Н	Н	Н	Н	31.35 ± 0.99
B-29	Н	CF ₃	Н	CF ₃	Н	ND
B-30	CF ₃	Н	F	Н	Н	ND
B-31	F	Н	CF ₃	Н	Н	23.11 ± 0.75
B-32	F	Н	Н	Н	CF ₃	29.17 ± 0.66
B-33	CF ₃	Н	Н	F	Н	27.79 ± 0.88
B-34	Н	F	Н	CF ₃	Н	29.11 ± 0.34
B-35	Н	CF ₃	F	Н	Н	ND
B-36	Н	Н	CH ₂ Cl	Н	Н	22.23 ± 0.85
B-37	Н	CH ₂ Cl	Н	Н	Н	20.05 ± 0.94
B-38	Н	Н	$N(CH_3)_2$	Н	Н	ND
B-39	Н	OCOCH ₃	H	Н	Н	ND
B-40	Н	H	OCOCH ₃	Н	Н	ND
PF			-			0.72 ± 0.06

SD-Standard Deviation, NA- Not Determined, *PF-Phosphorelated Flavonoid¹¹

Med

Absorption				Distribution			
Compound	Human	In vitro Caco-	In vitro MDCK	<i>In vitro</i> skin	In vitro plasma	In vivo blood	
	intestinal	2 cell	cell	permeability	protein binding	brain barrier	
	absorption	permeability	permeability	(logKp)	(%)	penetration	
	(HIA)%	(nm/sec)	(nm/sec)	cm/hr		(C.brain/C.blood)	
B-1	100.00	56.73	50.02	-2.65	95.97	2.75	
B-2	98.80	57.28	2.31	-2.80	95.48	0.08	
B-3	97.64	56.64	4.46	-2.93	93.63	0.04	
B-4	97.64	56.64	4.46	-2.93	93.03	0.04	
B-5	98.80	27.98	7.46	-1.73	96.49	1.70	
B-6	98.80	27.90	0.13	-1.73	99.05	1.36	
B-7	100.00	54.71	20.11	-2.91	98.40	2.17	
B-8	100.00	54.75	27.06	-2.94	100.00	0.28	
B-9	100.00	55.39	3.48	-2.94	100.00	0.24	
B-10	100.00	53.72	6,62	-3.06	99.69	1.82	
B-11	100.00	54.73	0.87	-3.09	100.00	0.30	
B-12	100.00	73.77	10.53	-3.12	100.00	0.30	
B-13	100.00	53.76	8.28	-3.09	100.00	0.39	
B-14	100.00	54.70	23.36	-3.09	100.00	0.38	
B-15	100.00	47.91	26.61	-2.70	96.47	0.42	
B-16	100.00	50.14	20.56	-2.62	100.00	0.80	
B-17	100.00	46.44	0.16	-2.57	100.00	1.27	
B-18	100.00	46.57	0.12	-2.58	100.00	0.45	
B-19	100.00	46.46	0.01	-2.58	100.00	0.46	
B-20	100.00	46.45	0.23	-2.62	100.00	1.07	
B-21	100.00	46.43	0.18	-2.6¢	View Article Online 39/C7MD0005.00	0.36	
B-22	98.49	21.43	0.42	-2.86	95.25	0.01	
B-23	98.49	15.17	0.33	-2.86	96.00	0.01	
B-24	96.03	20.38	0.06	-2.83	94.55	0.04	
B-25	100.00	56.22	5.38	-2.56	95.75	0.36	
B-26	100.00	41.23	0.93	-1.89	99.68	0.95	
B-27	100.00	41.36	0.07	-1.89	98.73	1.11	
B-28	100.00	41.61	3.42	-1.89	97.32	0.58	
B-29	100.00	42.14	0.04	-1.47	95.99	3.89	
B-30	100.00	48.21	0.15	-1.96	99.97	0.85	
B-31	100.00	47.41	0.07	-1.96	100.00	1.20	
B-32	100.00	47.73	1.05	-1.95	100.00	0.72	
B-33	100.00	47.72	1.22	-1.96	98.13	0.77	
B-34	100.00	48.21	0.06	-1.96	100.00	1.49	
B-35	100.00	48.63	0.04	-1.96	100.00	1.61	
B-36	100.00	25.60	2.79	-2.60	100.00	0.39	
B-37	100.00	25.58	18.06	-2.60	100.00	0.49	
B-38	100.00	57.87	0.37	-2.81	92.67	0.16	
B-39	97.37	45.13	2.63	-2.79	94.14	0.03	
B-40	97.37	48.99	0.22	-2.79	93.78	0.02	

Table 2. In silico ADME properties of 5,6-Benzoflavone derivatives

Compound	Molecular weight	No. of H- bond donors	No. of H- bond acceptors	Molar Refractivity	Log P	No. of Lipinski Violation
B-1	272	0	2	83.42	3.90	0
B-2	302	0	3	89.88	3.80	0
B-3	332	0	4	96.35	3.64	0
B-4	332	0	4	96.35	3.64	0
B-5	356	0	2	89.40	4.83	0
B-6	356	0	2	89.40	4.83	0
B-7	290	0	2	83.64	4.10	0
B-8	290	0	2	83.64	4.10	0
B-9	290	0	2	83.64	4.10	0
B-10	308	0	2	83.85	4.24	0
B-11	308	0	2	83.85	4.24	0
B-12	308	0	2	83.85	4.24	0
B-13	308	0	2	83.85	4.24	0
B-14	308	0	2	83.85	4.24	0
B-15	306	0	2	88.23	4.56	0
B-16	341	0	2	93.03	5.16	0
B-17	351	0	2	91.04	4.73	0
B-18	351	0	2	91.04	4.73	0
B-19	351	0	2	91.04	4.73	0
B-20	398	0	2	96.78	4.89	0
B-21	398	0	2	96.78	4.89	0
B-22	317	0	4	90ev75rticle Online	3.90	0
B-23	317	0	4	$\begin{array}{r} 90 \text{e7.5} \text{ticle Online} \\ \hline \text{DOI: } 10.1039/\text{C7MD00565B} \\ 90.75 \end{array}$	3.90	0
B-24	362	0	6	98.07	3.84	0
B-25	286	0	2	88.46	4.47	0
B-26	340	0	2	89.40	4.83	0
B-27	340	0	2	89.40	4.83	0
B-28	340	0	2	89.40	4.83	0
B-29	408	0	2	95.37	5.71	0
B-30	358	0	2	89.61	4.98	0
B-31	358	0	2	89.61	4.98	0
B-32	358	0	2	89.61	4.98	0
B-33	358	0	2	89.61	4.98	0
B-34	358	0	2	89.61	4.98	0
B-35	358	0	2	89.61	4.98	0
B-36	320	0	2	93.29	4.54	0
B-37	320	0	2	93.29	4.54	0
B-38	315	0	3	97.85	4.06	0
B-39	330	0	3	94.55	3.56	0
B-40	330	0	3	94.55	3.56	0

Table 3. Physicochemical parameters of 5,6-Benzoflavone derivatives

()

hemComm Accepted Manuscri


GRAPHICAL ABSTRACT

5,6-Benzoflavones as cholesterol esterase inhibitors: Synthesis, biological evaluation and docking studies

Jatinder V. Singh^I,^a, Anumeet Kaur^I,^a, Kavita Bhagat^a, Manish K. Gupta^b, Manwinder Singh^c, Harbinder Singh^{*},^a, Preet Mohinder S. Bedi^{*},^a

^aDepartment of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India ^bTERI-Deakin Nanobiotechnology Centre, The Energy and Resources Institute, TERI Gram, Gual Pahari, Gurugram, Haryana 122001, India

^cDepartment of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India



A library of forty 5,6-Benzoflavone derivatives was synthesized and evaluated for their inhibitory potential against cholesterol esterase (CEase) enzyme.